Next 10 |
2024-05-02 13:48:51 ET More on Moderna Moderna, Inc. (MRNA) Q1 2024 Earnings Call Transcript Moderna, Inc. 2024 Q1 - Results - Earnings Call Presentation Moderna Investors Should Beware Patent-Dispute Fallout Moderna tops forecasts in Q1 despite COVID-related...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
2024-05-01 02:59:23 ET More on GSK GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents Read...
2024-04-30 12:18:17 ET More on AstraZeneca, GSK, etc. AstraZeneca: A Triple Shot Of Income, Growth, And Value Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy AstraZeneca: Strong In A Weak Market GSK Q1 2024 Earnings Preview Ast...
2024-04-30 11:39:06 ET More on GSK GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript) GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy GSK sues Pfize...
2024-04-29 08:51:30 ET Summary Immatics N.V., a European T-Cell receptor therapy company, is expected to release clinical data on all four of its candidates in 2024. The company's main focus is on developing T-cell receptor therapies for the treatment of solid tumors. Immatics...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
2024-04-25 10:56:02 ET More on GSK GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript) GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy Sanofi reporte...
2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...
2024-04-23 13:32:13 ET More on Sanofi Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi succeeds in late-stage trial for ...
News, Short Squeeze, Breakout and More Instantly...
GlaxoSmithKline PLC Company Name:
GSK Stock Symbol:
NYSE Market:
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% e...
A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc.‘s (NASD...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...